CoChat
Sign Up
Cited by 168Menopause: Health Impacts and TreatmentsHormonal and reproductive studiesEstrogen and related hormone effects

Differential Effects of Oral Estrogen versus Oral Estrogen-Androgen Replacement Therapy on Body Composition in Postmenopausal Women

Dobs, Adrian S., Nguyen, Tam, Pace, Cindy, Roberts, Carla P.·2002·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jcem.87.4.8362
Open this paper in CoChat — free account

Abstract

Menopause is associated with decreased lean body mass and increased fat due to aging and declining hormone secretion. Estrogens or estrogen-progestins have been used to alleviate vasomotor symptoms. However, estrogen-androgen (E/A) therapy is also used for vasomotor symptom relief and has been shown to increase lean body mass while decreasing fat mass. The objective of this 16-wk, double-blind, randomized, parallel group clinical trial was to compare esterified estrogen plus methyltestosterone (1.25 mg estrogen + 2.5 mg methyltestosterone/d; E/A group) vs. esterified estrogen alone (1.25 mg/d; E group) on body composition. Forty postmenopausal women (mean age, 57 yr) participated. Compared with estrogen treatment alone, women in the E/A group increased their total lean body mass and reduced their percentage fat for all body parts (P < 0.05). After E/A treatment, there were statistically significant increases in lean body mass by 1.232 kg [0.181 +/- 0.004, 0.81 +/- 0.057, and 0.24 +/- 0.009 kg in the upper body (P = 0.021), trunk (P = 0.001), and lower body (P = 0.047), respectively]. In the E group, the increase was 0.31 +/- 0.004, 0.021 +/- 0.03, and 0.056 +/- 0.05 kg in the upper body, trunk, and lower body, respectively. In the E/A group, body fat was reduced by 0.90 kg (P = 0.18 for the trunk only), and percentage body fat declined by 7.4% (P < or = 0.05 for all body parts). Lower body strength increased by 23.1 kg (51 lb) in the E/A group vs. only 11 kg (24.25 lb) in the E group (P = 0.002 between groups). A statistically significant increase in weight (2.7 +/- 5.1 vs. 0.1 +/- 4.6 lb; P < 0.05) was observed in the E/A group compared with the E group. When subjects were given self-reporting questionnaires, more improvement was noted in sexual functioning and quality of life in the E/A group when compared with patients receiving E alone. There were no noteworthy side effects. In conclusion, E/A replacement therapy can improve body composition, lower-body muscle strength, quality of life, and sexual functioning in postmenopausal women.

Integrity signals

Registry

Crossref · 10.1210/jcem.87.4.8362

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In postmenopausal women, methyl testosterone after estrogen replacement significantly increased lean muscle mass and upper and lower limb power in a 16-week double-blind, parallel-group study.

    “Data corroborating the Huang et al. study results comes from another well-controlled study in which postmenopausal women who were administered methyl testosterone following a run-in period of estrogen replacement displayed a significant increase in lean (muscle) mass as well as upper and lower limb power during a 16-week double-blind, parallel group study (113).”

    From Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance (2018) · cites this paper as [113]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Dobs, A. S., Nguyen, T., Pace, C., & Roberts, C. P.
Affiliations
  • Johns Hopkins University (US)
  • Solvay (United States) (US)
Corresponding author
Dobs, Adrian S.
ORCID
Dobs, Adrian S.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2002-04-01
Volume
87
Issue
4
Pages
1509-1516
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jcem.87.4.8362
OpenAlex
W2135007207
Cited by
168
References
56
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 6 · 2016: 3 · 2015: 2 · 2014: 10 · 2013: 8 · 2012: 5
FWCI
7.41
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Center for Research Resources (M01 RR-00052, M01RR000052)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
Keywords
oral estrogen, esterified estrogens, methyltestosterone, body composition, lean body mass, fat mass, postmenopausal women, menopause, vasomotor symptoms, lower limb strength, weight gain, hormone replacement therapy, progestins, body fat distribution, trunk fat
MeSH terms
Administration, Oral, Aged, Anthropometry, Body Composition, Double-Blind Method, Estrogens, Female, Hormones, Humans, Lipids, Methyltestosterone, Middle Aged, Quality of Life, Sex, Weight Lifting, Estrogen Replacement Therapy, Postmenopause, Testosterone Congeners

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review